Allogeneic hematopoietic stem cell transplantation after CD19-directed CAR T-cell therapy in children and adults with B-cell acute lymphoblastic leukemia: a GoCART coalition study on behalf of the PDWP, ALWP, and CTIWP of the EBMT
Hematopoietic stem cell transplantation (HSCT) can rescue B-cell acute lymphoblastic leukemia (B-ALL) recurring after CD19-directed chimeric antigen receptor T cells (CAR19 T cells). However, in patients at high risk of relapse, the indication for and timing of consolidative HSCT are controversial. We retrieved data on 112 patients who received an HSCT at a median of 6.1 months after CAR19 T-cell infusion. Indication for subsequent HSCT were: (I) Rescue in 72 (64%) patients for disease recurrence; (II) Pre-emptive in 21 (19%) for loss of B-cell aplasia; (III) Consolidative in 19 patients (17%). The 2-year post-transplant Leukemia-Free Survival (LFS) was 54% and the 2-year cumulative incidence of relapse was 32%. Children had better LFS than adults (63% vs 38%). Older age was associated with inferior LFS (HR per 10-year increase 1.30; p= 0.01) and patients receiving a rescue HSCT had a significantly lower 2-year LFS (41%), compared to pre-emptive (74%) and consolidative HSCT (78%), respectively (p=0.002). Haploidentical donor was also associated with inferior LFS (HR: 2.21 95%CI: 1.15-4.25, p=0.02). This "real-world" study corroborates the need to identify patients at higher risk of relapse and optimization of strategies to improve outcome in patients with R/R B-ALL receiving CD19-directed CAR T cells.
Authors
- Shatha Farhan (ORCID: https://orcid.org/0000-0002-5723-7442)
- Krzysztof Kałwak (ORCID: https://orcid.org/0000-0003-1174-5799)
- Julio Delgado (ORCID: https://orcid.org/0000-0002-5157-4376)
- Anne-Charlotte Teyssier (ORCID: https://orcid.org/0000-0002-9401-2103)
- Júlia Marsal
- Fabio Ciceri (ORCID: https://orcid.org/0000-0003-0873-0123)
- Pere Barba (ORCID: https://orcid.org/0000-0001-7076-7969)
- Sebastian Giebel (ORCID: https://orcid.org/0000-0002-4827-4401)
- Valentín Ortiz‐Maldonado (ORCID: https://orcid.org/0000-0003-4699-6862)
- Stephan Mielke (ORCID: https://orcid.org/0000-0002-8325-9215)
- Yves P. Beguin (ORCID: https://orcid.org/0000-0003-4650-7520)
- Giorgio Ottaviano (ORCID: https://orcid.org/0000-0003-3777-0394)
- Arnon Nagler (ORCID: https://orcid.org/0000-0002-0763-1265)
- Jacques‐Emmanuel Galimard (ORCID: https://orcid.org/0000-0001-9102-4427)
- Anna Alonso‐Saladrigues (ORCID: https://orcid.org/0000-0002-3195-5470)
- Samppa J. Ryhänen (ORCID: https://orcid.org/0000-0003-4431-643X)
- Núria Martínez‐Cibrián (ORCID: https://orcid.org/0000-0002-8688-1202)
- Adriana Balduzzi (ORCID: https://orcid.org/0000-0002-5879-0610)
- Annalisa Ruggeri (ORCID: https://orcid.org/0000-0002-7261-2765)
- Eva Michel
- Soeren Lykke Petersen
- Antonio Pérez Martínez
- Fizza Imran
- Jurgen Kuball
- Andishe Attarbaschi
- Susana Rives
- Sowjana Vuyyala
Institutions
- Hospital Sant Joan de Déu Barcelona (ES)
- Mayo Clinic (US)
- University of Helsinki (FI)
- Henry Ford Health System (US)
- University of Liège (BE)
- Sheba Medical Center (IL)
- Hospital Universitario La Paz (ES)
- Copenhagen University Hospital (DK)
- Rigshospitalet (DK)
- Henry Ford Hospital (US)
- Karolinska Institutet (SE)
- University Medical Center Utrecht (NL)
- Wroclaw Medical University (PL)
- Centre Hospitalier Universitaire de Montpellier (FR)
- Azienda Ospedaliera San Gerardo (IT)
- Hospital Clínic de Barcelona (ES)
- St Anna Children's Hospital (AT)
- Vall d'Hebron Hospital Universitari (ES)
- IRCCS Ospedale San Raffaele (IT)
- Centre Hospitalier Universitaire de Liège (BE)
- The Maria Sklodowska-Curie National Research Institute of Oncology (PL)
- European Society for Blood and Marrow Transplantation (FR)
- Institut de Recerca Sant Joan de Déu (ES)
- University of Milano-Bicocca (IT)
Publication Details
- Journal
- Haematologica
- Published
- 2026-11-19
- DOI
- https://doi.org/10.3324/haematol.2026.301354
- Primary Topic
- CAR-T cell therapy research
- Type
- article
- Field-Weighted Citation Impact
- 0.00